当前位置：
X-MOL 学术
›
Pharmacol. Rev.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates
Pharmacological Reviews ( IF 19.3 ) Pub Date : 2024-07-01 , DOI: 10.1124/pharmrev.123.001084 Zhiwen Huang 1 , Zachary Braunstein 1 , Jun Chen 1 , Yingying Wei 1 , Xiaoquan Rao 2 , Lingli Dong 2 , Jixin Zhong 2
Pharmacological Reviews ( IF 19.3 ) Pub Date : 2024-07-01 , DOI: 10.1124/pharmrev.123.001084 Zhiwen Huang 1 , Zachary Braunstein 1 , Jun Chen 1 , Yingying Wei 1 , Xiaoquan Rao 2 , Lingli Dong 2 , Jixin Zhong 2
Affiliation
|
In the era of precision medicine, antibody-drug conjugates (ADCs) have emerged as a cutting-edge therapeutic strategy. These innovative compounds combine the precision of monoclonal antibodies with the potent cell-killing or immune-modulating abilities of attached drug payloads. This unique strategy not only reduces off-target toxicity but also enhances the therapeutic effectiveness of drugs. Beyond their well established role in oncology, ADCs are now showing promising potential in addressing the unmet needs in the therapeutics of rheumatic diseases. Rheumatic diseases, a diverse group of chronic autoimmune diseases with varying etiologies, clinical presentations, and prognoses, often demand prolonged pharmacological interventions, creating a pressing need for novel, efficient, and low-risk treatment options. ADCs, with their ability to precisely target the immune components, have emerged as a novel therapeutic strategy in this context. This review will provide an overview of the core components and mechanisms behind ADCs, a summary of the latest clinical trials of ADCs for the treatment of rheumatic diseases, and a discussion of the challenges and future prospects faced by the development of next-generation ADCs.
中文翻译：
风湿病精准医学：释放抗体药物偶联物的潜力
在精准医疗时代，抗体药物偶联物（ADC）已成为一种前沿的治疗策略。这些创新化合物将单克隆抗体的精确性与所附药物有效负载的有效细胞杀伤或免疫调节能力结合在一起。这种独特的策略不仅减少了脱靶毒性，而且增强了药物的治疗效果。除了在肿瘤学中的既定作用之外，ADC 现在在解决风湿性疾病治疗中未满足的需求方面显示出巨大的潜力。风湿病是一组具有不同病因、临床表现和预后的慢性自身免疫性疾病，通常需要长期的药物干预，迫切需要新颖、有效和低风险的治疗方案。 ADC 凭借其精确靶向免疫成分的能力，已成为这种背景下的一种新型治疗策略。本综述将概述ADC背后的核心成分和机制，总结ADC治疗风湿性疾病的最新临床试验，并讨论下一代ADC开发面临的挑战和未来前景。
更新日期：2024-06-14
中文翻译：
风湿病精准医学：释放抗体药物偶联物的潜力
在精准医疗时代，抗体药物偶联物（ADC）已成为一种前沿的治疗策略。这些创新化合物将单克隆抗体的精确性与所附药物有效负载的有效细胞杀伤或免疫调节能力结合在一起。这种独特的策略不仅减少了脱靶毒性，而且增强了药物的治疗效果。除了在肿瘤学中的既定作用之外，ADC 现在在解决风湿性疾病治疗中未满足的需求方面显示出巨大的潜力。风湿病是一组具有不同病因、临床表现和预后的慢性自身免疫性疾病，通常需要长期的药物干预，迫切需要新颖、有效和低风险的治疗方案。 ADC 凭借其精确靶向免疫成分的能力，已成为这种背景下的一种新型治疗策略。本综述将概述ADC背后的核心成分和机制，总结ADC治疗风湿性疾病的最新临床试验，并讨论下一代ADC开发面临的挑战和未来前景。
京公网安备 11010802027423号